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Abstract
Background: Neuronal Ca2+ dyshomeostasis and hyperactivity play a central role in Alzheimer’s disease pathology
and progression. Amyloid-beta together with non-genetic risk-factors of Alzheimer’s disease contributes to
increased Ca2+ influx and aberrant neuronal activity, which accelerates neurodegeneration in a feed-forward
fashion. As such, identifying new targets and drugs to modulate excessive Ca2+ signalling and neuronal
hyperactivity, without overly suppressing them, has promising therapeutic potential.
Methods: Here we show, using biochemical, electrophysiological, imaging, and behavioural tools, that pharmacological
modulation of Rap1 signalling by inhibiting its interaction with Pde6δ normalises disease associated Ca2+ aberrations
and neuronal activity, conferring neuroprotection in models of Alzheimer’s disease.
Results: The newly identified inhibitors of the Rap1-Pde6δ interaction counteract AD phenotypes, by reconfiguring Rap1
signalling underlying synaptic efficacy, Ca2+ influx, and neuronal repolarisation, without adverse effects in-cellulo or in-
vivo. Thus, modulation of Rap1 by Pde6δ accommodates key mechanisms underlying neuronal activity, and therefore
represents a promising new drug target for early or late intervention in neurodegenerative disorders.
Conclusion: Targeting the Pde6δ-Rap1 interaction has promising therapeutic potential for disorders characterised by
neuronal hyperactivity, such as Alzheimer’s disease.
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Background
Neuronal hyperactivity and chronically elevated cytosolic
calcium [Ca2+]i are among the earliest pathological events
in both familial and sporadic Alzheimer’s disease (AD) [1–
4]. Amyloid-beta (Aβ), a peptide which progressively aggre-
gates around neurons during the disease, appears to play an
important role in driving these aberrations, as in the vicinity
of Aβ accumulations (or plaques), where concentrations of
soluble oligomeric Aβ (Aβo) are highest, neurons have a
tendency to be hyperactive [5]. These AD associated
changes in neuronal activity appear to involve, at least in
part, a direct or indirect modulation of Ca2+ permeable
receptors and ion channels as well as the disruption of lipid
barriers by Aβo [6].
Apart from Aβ, also Tau, the second major aggregating
protein crucial for AD progression, has signalling func-
tions, involving Ca2+, and plays a role in excitability and
network synchronisation [7, 8]. Of particular interest in
this regard is dendritic Tau, which facilitates Ca2+ influx
during Aβ induced neurotoxicity [7, 9]. An additional in-
dication for the prominent role of Tau in AD is that, in
animal models of the disease, the depletion of the former
protein prevented Aβ associated neuronal hyperactivity
and cognitive deficits [10, 11]. Thus, the interplay between
Aβ and Tau in AD is essential for driving Ca2+ aberrations
and excessive neuronal activity.
Moreover, neuronal hyperactivity and Ca2+ dyshomeosta-
sis are not only the consequences of pathological Aβ and
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Tau but in turn also accelerate their formation. Aberrant
Ca2+ signalling was shown to facilitate Tau phosphorylation
[12] and Aβo production [13, 14], the precursors of the
well-known AD hallmarks – neurofibrillary tangles and
amyloid plaques respectively. Hence, it can be envisaged
that risk factors for sporadic AD, which impair Ca2+
homeostasis (most notably ageing) [1, 6], set-off a neuro-
toxic cascade leading to neuronal hyperexcitability and ab-
errant network activity resulting in enhanced formation of
Aβo and Tau phosphorylation. These aberrations in turn
reinforce the disease cascade in a feed-forward fashion,
bringing about progressive neuronal degeneration [15]. In
case of familial AD, the same pathological sequence of
events can be directly and potently initiated by genetic mu-
tations which increase Aβo formation [16, 17].
The importance of excessive neuronal activity in light of
the pathology is emphasised by recent findings linking en-
hanced cognitive deficits, accelerated symptoms and greater
neuronal loss in AD to patients suffering from spontaneous
non-motoric seizures (10–22% of AD population), com-
pared to other AD patients [18]. In addition, treatments tar-
geting abnormal neuronal activity, including the anti-
epileptic drug levetiracetam, have shown to improve cogni-
tive performance in mouse models of the disease [10, 19]
and are currently under investigation in patients with AD
during clinical trials (e.g.: NCT02002819) [20].
Collectively, these mechanistic underpinnings indicate
that normalising Ca2+ homeostasis and hyperactivity
represent a promising therapeutic paradigm. However,
given the fundamental nature of Ca2+ signalling in cell
physiology, targeting such deregulations in a safe fashion
represents a major challenge. Here we addressed this
problem by screening directly for therapeutic com-
pounds using a neuronal cell based phenotypic screen
that mimics crucial mechanisms underlying AD and by
subsequently identifying their corresponding cellular tar-
get conferring neuroprotection.
Methods
Mice, drug treatment, behavioural testing and
termination
Human mutant transgenic APP-V717I [21] (hAPP) and
APP-V717I*PS1-A246E [22] (hAPP*PS1) mice in FVB/
NxC57Bl/6 J background and age-, sex- and background-
matched wild-type (WT) mice with ad libitum access to
food and water were used. Breeding and housing for elec-
trophysiological studies was in conventional 12 h light/dark
cycle. Housing of mice for behaviour and biochemistry was
in inverted 12 h light/dark cycle. All animals used in this
study were female and four mice were housed per cage.
Overexpression of human transgenes is steered by the
mouse neuron-specific Thy1 gene promotor. All experi-
mental procedures were performed in accordance with the
Guide for the Care and Use of Laboratory Animals (NRC,
2011) and the European Communities Council Directive of
September 22nd, 2010. REM0043039 was dissolved in lipo-
somes (Phares, Switzerland).
For chronic treatment of REM, hAPP and hAPP*PS1
mice were injected daily subcutaneously (sc) with vehicle or
compound at 20 mg/kg. For acute REM effects, mice were
dosed orally at 30 mg/kg achieving (similarly to sc dosing) a
sufficiently high free compound concentration in brain.
Pharmacokinetic assessments, prior to the commencement
of studies, had indicated that both dosing regimens resulted
in sufficient compound levels for target engagement (data
not shown).
hAPP*PS1 used for biochemistry were dosed during 14
consecutive days before termination at the age of 6 months.
For behaviour studies, daily treatment of hAPP and con-
trol mice started at the age of 4.5 months. After 8 weeks
treatment (around 8 months of age) hAPP and control
mice were tested in the Morris water maze (MWM) para-
digm. Therefore, mice were trained to find the hidden es-
cape platform (10 cm diameter, 1.5 cm submerged below
the surface) in a pool (160 cm diameter) filled with white
opaque water (23–24 °C) during 4 consecutive days and 4
trials per day (with a maximum of 90 s trial and an
inter-trial interval of 120 min). Both intra- and extra-maze
cues were present. During the first day mice were allowed
to sit on the platform for 10 s before being taken out of
the pool. Mice that did not mount the platform were gen-
tly guided to it. The platform location remained constant
throughout the 4 training days. However, the drop location
of the mice varied semi-randomly among trials. For the
probe trial on day 5 the platform was removed, and mice
were allowed to swim for 60 s. The swimming pattern of
the mice was video-monitored using a CCD camera and
analysed using dedicated software (EthoVision, Noldus,
The Netherlands). Search path (cm) and the annulus
crossing index (ACI, defined as the frequency of crossing
the target platform region minus the averaged imaginary
platform regions in the other quadrants) were used as pri-
mary read-out during learning and probe trial, respectively.
At the end of the study, all mice were terminated.
Cell culture
For construction of hTAU-P301L cells a TAU expres-
sion plasmid was constructed by sub-cloning the cDNA
of human TAU-P301L (encoding for TAU with proline
301 substituted by a leucine residue) into mammalian
expression vector pcDNA3.1 resulting in plasmid
pcDNA3.1-TAU P301L. Plasmid pcDNA3.1-TAU-P301L
were transfected into human BE(2)-M17neuroblastoma
cells (ATCC No. CRL-2267) with the plasmids stably inte-
grated into the genome were selected. These resulted in
the cell line referred to as hTau-P301L. Expression of the
hTAU-P301L gene in the cell lines was confirmed by
Western blot analysis (Additional file 1: Figure S1a).
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hTAU-P301L cells were cultured in culture medium con-
taining Opti-MEM Reduced Serum Medium with phenol
red supplemented with 1 mM sodium pyruvate, 1 x
non-essential amino acids, 500 μg/ml G418 0,5 x antibiotic/
antimycotic, antibiotics and 10% foetal calf serum (FCS).
For the cellular toxicity assay hTAU-P301L cells were
seeded at 2500 cells/cm2 in 96-well microplates, in ex-
periment medium containing Opti-MEM Reduced
Serum Medium without phenol red supplemented with
1 mM sodium pyruvate, 1 x non-essential amino acids,
500 μg/ml G418 0,5 x antibiotic/antimycotic, antibiotics
and 1% FCS. After 3 h of incubation at 37 °C/5% CO2,
100 μl of experiment medium without FCS supple-
mented with all-trans retinoic acid (ATRA) (final con-
centration 3.75 μM) and compound dissolved in
dimethyl sulfoxide (DMSO) or vehicle alone (final con-
centration DMSO 2%) was added. The cells were fur-
ther incubated for 7 days at 37 °C/5% CO2.
Subsequently, Lactate dehydrogenase (LDH) activity
was determined using Promega Cytotox 96 Non-Radio-
active cytotoxicity assay (Cat. G1780), according the
supplier’s instructions and the percentage LDH in the
growth medium was calculated as a measure for tox-
icity using the following formula (slopes are calculated
from the measured kinetic A492 values in function of
time):
Toxicity ¼ slope of released LDH dead cellsð Þ
slope of total LDH dead þ viable cellsð Þ :
Primary hippocampal cultures were prepared from
CD-1 (Swiss) embryonic day 16 (E16) mouse brains and
plated on culture plates or glass coverslips coated with
(0.1 mg/ml) poly-D-lysine (PDL) and (0.002 mg/ml) lam-
inin or PDL pre-coated plates (Greiner) were used. Cul-
tures were grown in serum free Neurobasal medium
(NB, Gibco) supplemented with B27 (Gibco), glutamax
(Gibco) and penicillin/streptomycin (50 u/ml) in multi-
well plates at a density of 0.15 × 106 cells per ml. Culture
medium was refreshed twice a week.
siRNA transfection
For gene silencing experiments hTAU-P301L neuroblast-
oma cells were plated out 24 h before transfection in
6-well plates. Cells were with Lipofect-amine® RNAi-
MAX (Thermo Fisher) according to the Thermo Fisher’s
“forward transfection protocol” with a final siRNA con-
centration of 25 pmol. RNA sequences used were siRNA
Rap1A (Thermo Fisher, #4390771, s11779), siRNA ret-
inal rod rhodopsin-sensitive cGMP 3′,5′-cyclic phospho-
diesterase subunit delta (Pde6δ, protein ID: O43924)
(Thermo Fisher, #4390771, s10207) and scrambled nega-
tive siRNA control (Thermo Fisher, #4390843). Twenty-
four hours post-transfection the cells were re-plated into
96-well microplates for the toxicity assay.
Biochemical pull-down: Pde6δ and REM-MTX interaction
assay
The cDNA encoding PDE6δ was sub-cloned into the
vector pPR-IBA102 in frame with the upstream Strep
tag. The resulting construct was used to express protein
using a Mini Expressway cell-free E. coli expression sys-
tem (Life Technologies) according to the manufacturer’s
instructions. Correct expression was confirmed using
Western blot analysis with the StrepMAB-Classic anti-
body (data not shown).
For the interaction assay, E. coli cell-free lysate con-
taining Strep-PDE6δ and methotrexate fused REM com-
pound (REM-MTX) or the corresponding amount of
DMF were mixed and incubated on ice for 3 h to
achieve binding of the compound to the target. Subse-
quently, equilibrated Strep-Tactin Sepharose beads were
added and incubated for 90 min at 4 °C with over-end
rotation. Excess compound was removed by washing the
beads 3 times with wash buffer (20 mM Tris-Cl pH 7.4,
150 mM NaCl). After removal of the last wash E. coli
cell-free lysate containing His-DHFR in wash buffer was
added to each sample, followed by incubation for 60 min
at 4 °C with over-end rotation. After flow through re-
moval and 3 subsequent washes, the beads were eluted
with elution buffer containing 10 mM Desthiobiotin for
30 min on ice. Samples were mixed with SDS sample
buffer for SDS-PAGE analysis and Western blot and
analysed with an Anti-HisG antibody.
Affinity purification coupled with mass spectrometry to
identify interactors with Pde6δ
The cDNA encoding human Pde6δ was fused with a
Strep-HA tag encoding DNA sequence and sub-cloned into
a standard expression vector. The bait sequence was
verified by sequencing. For constitutive overexpression, the
expression vector containing the gene encoding the bait
Pde6δ-Strep-HA was transfected into HEK293 cells and se-
lected for stable integration. Bait expression and solubility
was monitored by immunoblotting using anti-HA anti-
bodies. For affinity purification, protein extracts were
prepared from control (HEK293 cells not expressing
Pde6δ-Strep-HA), vehicle (DMSO) and compound treated
Pde6δ-Strep-HA bearing cells under specific lysis condi-
tions and the fusion protein was pulled-down using
Strep-Tactin Sepharose beads. Affinity purification and
mass spectrometry analysis of Pde6δ-Strep-HA expressed
in HEK293 cells was performed with three biological
replicates. For label free quantitative mass spectrometry
analysis samples were analysed on a Thermo LTQ Orbitrap
XL spectrometer using a C18 column, ESI and a 60 min
gradient. The signals’ intensity is provided as 2 Log values
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and correlates to the concentration of the detected mass
(number/amount of peptide). The variation within the
biological replicates for control, vehicle-treated Pde6δ pull-
down, and REM treated Pde6δ pulldown was below 10%. A
Co-precipitation threshold of 2 (Pde6δ vehicle /control
value) is set to decide on the interacting properties of a pro-
tein to Pde6δ. For interacting proteins, signals were back-
ground corrected and REM treated samples were
normalised to the DMSO control samples to identify for
Pde6δ-protein interactions inhibited by REM.
Ca2+ recordings
For basal Ca2+ measurement in the neuroblastoma tox-
icity model, cells were loaded with Fura-2 AM (Sig-
ma-Aldrich), a cell permeable fluorescent probe for Ca2+
at day 6 of the experiment. Briefly, Fura-2-AM was dis-
solved in DMSO plus 20% pluronic acid (0.025% final
assay concentration (Invitrogen)) in a 1:1 ratio and di-
luted in medium to a final concentration of 0.5 μM. Pro-
benecid (Sigma-Aldrich) is added to this loading
medium at a final concentration of 2.5 μM. Then, cul-
ture medium is replaced by loading medium and after
incubation for 1 h at 37 °C cells in the dark were washed
and incubated in HBSS (Gibco) supplemented with 0.2%
FCS (Gibco) and 0.02 M HEPES (Gibco) before Ca2+ be-
ing recorded in the FlexStation 3 (Molecular Devices).
Cells were excited at 340 nm (Ca2+ bound Fura-2) and
380 nm (Ca2+ unbound Fura-2) of the FlexStation 3 with
emission at 510 nm (cut-off filter 475 nm) in well scan
modus (9 points/well).
Days in-vitro (DIV) > 14 hippocampal neurons were
treated 24 h prior to experiment with 1.5 μM REM or
equivalent amount of vehicle and were present through-
out the experiment. One hour prior to Ca2+ recordings,
primary neurons were incubated with loading medium
containing 2 μM of the cell permeable Ca2+-indicator
Fura-2 AM, 0.02% pluronic acid (F-127) (Invitrogen)
and 2.5 μM Probenecid (Sigma-Aldrich) for 30 min at
37 °C in the dark. After loading, cells were washed and
incubated in HBSS (Gibco) supplemented with 10 mM
HEPES (Gibco) (with or without 12.5 μM nifedipine/ve-
hicle) and/or 1.5 μM REM/vehicle for 30 min, in the
dark, at room temperature. Cells were then excited at
340 nm and 380 nm in time with the flex mode of the
FlexStation 3, recording 4 reads per well every 3.6 s.
Emissions were collected at 510 nm (cut-off filter
475 nm). After 60 s of “background reading”, HBSS-
HEPES containing high KCl (with adjusted monovalent
ion concentration – variable amounts of NaCl/KCl, as
previously described [23]) or HBSS-HEPES “control so-
lution” was added to the cells and emissions were read
further for four minutes.
Overall, changes in [Ca2+]i were quantified, by making
the ratio of changes in the amount of cytosolic Ca2+
bound Fura-2 (fluorescence intensity at 340 nm) relative
to the amount of Ca2+ unbound Fura-2 (fluorescence in-
tensity at 380 nm). Area under the curves (AUC) was
calculated after normalising the data to the average base-
line (first 60 s of recording) values. Data was processed
with SoftMax Pro 5.4.6 software (Molecular Devices).
Electrophysiology (acute brain slices, sAP, firing rate, LTD)
Acute sagittal brain slices from WT or hAPP mice were
prepared by decapitation of the mice after isoflurane an-
aesthesia. Brains were removed quickly and immersed
during 3–4 min in ice-cold freshly prepared cutting artifi-
cial cerebrospinal fluid (cutting aCSF) containing (in mM)
214 sucrose, 2.5 KCl, 2 CaCl2, 2 MgSO4, 1.25 NaH2PO2,
26 NaHCO3 and 10 glucose and oxygenated with 95% O2/
5% CO2. Sagittal 350 μm slices were generated using a
vibratome (VT 1000S; Leica Microsystems) and were
incubated in standard carboxygenated aCSF (in mM: 125
NaCl, 2.5 KCl, 2 CaCl2, 2 MgSO4, 1.25 NaH2PO2, 26
NaHCO3 and 10 glucose, osmolarity 305 mOsm) at 34 °C
for 20 min. The incubation continued at room temperature
(RT) for another hour before each slice was transferred to
a submerged recording chamber and perfused continu-
ously with carboxygenated aCSF.
Somatic or dendritic (approximately 250 μm from the
soma) current-clamp recordings were performed on
slices from mice aged 3–4 months at RT (24 to 28 °C).
The slices were continuously perfused with carboxyge-
nated standard aCSF. Depending on the experiment,
aCSF was supplemented with control or test article
REM0043039 at 2 μM. For whole-cell recordings, patch
pipettes were filled with a solution containing (in mM)
140 K-gluconate, 5 NaCl, 2 MgCl2, 10 HEPES, 0.5
EGTA, 2 MgATP, 0.4 NaGTP, osmolarity 305, pH ad-
justed to 7.25 with KOH. The soma or dendrite of large
CA1 pyramidal neurons were identified and patch-
clamped after visual approach of the recording pipette
using a combination of infrared light and differential
interference contrast (DIC) optics. Patch electrodes had
a resistance of around 5 and 14 MΩ when filled for
somatic and dendritic recording, respectively. Record-
ings were terminated when the series resistances
exceeded 40 MΩ. Signals were digitised, and low-pass
filtered at 10 kHz. The signal was amplified with an
Axopatch 200B amplifier, digitised by a Digidata 1550
interface and sampled with Clampex 10 (Molecular
Devices).
For the single AP experiment, a single spike was elicited
by injecting a 2 milliseconds depolarising current pulse.
The following action potential (AP) parameters were ana-
lysed: AP area, AP amplitude, AP delay, AP half-width,
AP rising slope, AP decay slope, afterhyperpolarisation
(AHP) amplitude (calculated by subtracting the minimum
value following the AP from the resting membrane
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potential), AHP half-width and AHP time-to-peak. Som-
atic single AP recordings were performed at baseline and
after 25 min vehicle or compound perfusion. Dendritic
single AP recording occurred after at least one hour ve-
hicle or compound incubation and throughout the experi-
ment in perfusion.
Dendritic firing rate of CA1 cells was recorded in response
to hyperpolarising and depolarising steps (− 0.2 to + 0.45 nA,
steps of 0.05 nA) after at least one hour incubation with ve-
hicle or compound at 2 μM and throughout the experiment
in perfusion. The mean number of action potentials (firing
rate) was plotted in function of current step intensity. In
addition, AP amplitude, AP onset, AP threshold, AHP ampli-
tude, input resistance and current-voltage relation were ana-
lysed. Results were corrected for vehicle effect.
Somatic voltage-clamp recording of CA1 cells was per-
formed to determine total (P1) and IA-type potassium
(K+) currents (P2). Electrodes were filled with an intracel-
lular solution containing (in mM) 145 KCl, 1 MgCl2, 10
EGTA, 0.2 CaCl2, and 10 HEPES buffer (Sigma). Tetrodo-
toxin (TTX; 1 mM) and CdCl2 (0.3 mM) were added into
the aCSF to block Na+ voltage dependent channels and
Ca2+ channels, respectively. Membrane potential was held
at − 60 mV. Depolarising potential steps were preceded by
300 milliseconds hyperpolarising pulse at − 120 mV (volt-
age protocol P1) to evoke outward currents including IA.
IA was inactivated by a 50 milliseconds prepulse at +
10 mV (voltage protocol P2). IA was obtained by subtract-
ing the current evoked from P2 from that evoked from P1
(Klee et al. 1997; Numann et al. 1987). The amplitude of
IA was measured at the peak of the current (at 20 millisec-
onds after the onset of testing pulses).
MGluR-mediated long-term depression (LTD) was in-
duced by perfusion of 50 μM (S)-3,4-dihydroxyphenyl-
glycine (DHPG; Tocris) to WT (C57Bl/6 J background,
6–8 weeks old) brain slices for 5 min. DHPG was dis-
solved in H2O at a stock concentration of 50 mM and
aliquots were stored at − 80 °C until dilution into aCSF.
Field excitatory postsynaptic potentials (fEPSPs) record-
ings were performed in the stratum radiatum using a
borosilicate micropipette filled with aCSF in a sub-
merged chamber continuously perfused with a CSF at
1.1 ml/minute. The signal was amplified with an Axo-
patch 200B amplifier, digitised by a Digidata 155 inter-
face and sampled with Clampex 10 (Molecular Devices).
Before baseline fEPSP recording and perfusion of DHPG,
brain slices were preincubated in aCSF supplemented
with vehicle or compound at 2 μM for 80 min. Perfusion
of vehicle or compound continued during fEPSP record-
ing up to 60 min after DHPG addition.
For the biochemical analysis of DHPG-induced LTD in
primary cells, DIV 19–22 hippocampal neurons were
pre-treated > 30 min prior to 50 μM DHPG with 1 μM
TTX (Tocris) as well as 1.5 μM REM0043039 or vehicle
(DMSO). DHPG was weighed freshly to make up a stock
of 25 mM in sterile H2O. After 30 min, DHPG added to
the cells at a final concentration of 50 μM for 10 min.
Cells were lysed on ice for ten minutes in RIPA Buffer
(Thermo Fisher) containing 1× HaltTM Protease and
Phosphatase Inhibitor Cocktail (Thermo Fisher) and
debris was removed by centrifuging the homogenate at
14.000 x g for 10 min at 4 °C. Samples were stored at −
80 °C until further use.
Tissue/cell processing and Western blot analysis
Cortex samples of hAPP*PS1 mice were homogenised
using a potter-type mechanical homogeniser (VOS
14 S40, rate ~ 750 rpm VWR) in 6.5 weight-volumes of
cold tris-protease-phosphatase-inhibition buffer (TPPI--
buffer) containing (in mM) 50 Tris-HCl (pH 8.1), 250
saccharose, 3 MgCl2, 1 EDTA, 1 EGTA and a cocktail of
HaltTM protease and phosphatase inhibitors (Thermo
Fisher). Whole extract was aliquoted and stored at − 80 °
C until further use.
Tissue whole protein extracts were diluted with an
equal volume of SDS-PAGE sample buffer (containing
final concentrations of 1% (w/v) SDS and 2.5% (v/v)
2-mercaptoethanol) and were denatured and reduced by
incubation at 95 °C for 10 min. The same was done for
Cell extracts after adjusting amounts of protein and vol-
ume for each sample (determined using Biorad’s DC
protein assay (Biorad)). Proteins were separated on 4–
12% Bis-Tris or 7.5% Tris-HCl gels (Criterion XT Pre-
cast Gel, 26 well, 15 μl, 1.0 mm; Biorad). After semi-dry
electrotransfer (iBlot™, Invitrogen) to PVDF-membranes
(iBlot™ Gel Transfer Stacks, PVDF, Regular, Invitrogen),
the membranes were incubated 2 h or overnight in tris-
buffered saline (TBS, pH 7.6) with 0.1% (v/v) Tween-20
containing either 5% (w/v) non-fat dry milk or 5% bo-
vine serum albumin (BSA) (depending on primary anti-
body). The next day, the blots were incubated with
primary antibody for 2 h or overnight. After washing
and incubation for at least 2 h with an HRP-conjugated
secondary antibody (goat-anti-mouse or goat-anti-rabbit
IgG, DAKO; goat-anti-rabbit IgG, Cell Signaling) blots
were developed by the ECL detection system (LiteAblotR
Plus ECL substrate, EuroClone; or SuperSignal West
Femto Maximum Sensitivity Substrate, product 34096,
Thermo Fisher) and images were recorded digitally
(VisionWorks Acquisition, UVP) at different exposure
times. Dedicated software (VisionWorks Analysis, UVP)
was used for densitometric analysis.
Primary antibodies used: rabbit p44/42MAPK (ERK1/
2) (Cell Signaling, #4695), rabbit phospho-p44/42MAPK
(ERK1/2) (Thr202/Thr204) (Cell Signaling, #4370),
rabbit alpha-Tubulin (Abcam, ab24246), rabbit GAPDH
(Abcam), rabbit Rap1A (Novus Biologicals, NBP1–
97-489), rabbit Pde6δ (Genetex, GTX109240), mouse
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AD2 (Biorad, #56484), pS262 Tau (ProSci, XBP-4276),
pan-Tau (Tau5, Calbiochem, #577801), HT7 Tau (human
Tau, Thermo Fisher, MN1000). HRP-conjugated second-
ary goat anti-rabbit (Dako), goat anti-mouse (Dako) and
goat-anti-rabbit (Cell Signaling) antibodies were used.
Docking procedures
All calculations were carried out using Schrodinger Suite
software [24] with default parameters except when
otherwise specified. High resolution X-ray crystal struc-
ture of farnesylated Rheb in complex with Pde6δ [25],
PDB code 3T5G, was selected to perform molecular
modelling calculations. Rheb protein atoms were deleted
to give the starting structure of isolated Pde6δ in complex
with farnesyl moiety fused to terminal Rheb cysteine resi-
due. Protein preparation was then performed in order to
add hydrogen atoms, to remove water molecules or to
identify possible interacting water, to fix missing sidechain
atoms or missing residues, to assess protonation state of
ionisable amino acids. Docking simulations were per-
formed using GlideXP (extra precision).
Statistical analysis and data collection
To assess whether the means of two groups are
statistically different from each other, we used an
unpaired two-tailed t-test unless specified otherwise.
Ordinary two-way ANOVA was applied to compare
differences in the mean between groups with two in-
dependent variables followed by Sidak’s test for mul-
tiple comparisons as post-hoc analysis unless stated
otherwise. Where appropriate, the Grubb’s method
(alpha = 0.05) was used to identify outliers.
For all ex-vivo electrophysiology and in-vivo studies
both animals and treatment were randomly allocated to
a treatment group (digital randomisation occurred in
Excel using the rand-function). In-vivo and ex-vivo prac-
ticalities and analysis of data was always performed in a
blind manner after which the treatment groups were
decoded by the study director.
All statistical analysis was done with the Prism 7
software (GraphPad). Values are given as mean ±
standard error of the mean unless indicated other-
wise. Error probabilities of P < 0.05 were considered
statistically significant. Indication of p-value summar-
ies: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
or ####p < 0.0001.
Target identification screen
A three-hybrid approach used to identify the target as de-
scribed [26, 27]. To this end REM0043037 (B1) was fused
with methotrexate, finally resulting in REM0044931 (B3),
as a tool compound for identifying interacting proteins
was prepared (see “Preparation of fusion compound used
for the target identification screen”).
Preparation of fusion compound used for the target
identification screen
Abbreviations: CC – Column chromatography; DCM – Di-
chloromethane; TEA – Triethylamine; DMF – N,N-di-
methylformamide; BOP: (benzotriazol-1-yloxy) tris
(dimethylamino) -phosphonium hexafluorophosphate; TLC
– Thin layer chromatography; DMSO. Analysis by
LC-MS-UV was carried out on an Agilent system with a
3 × 150 mm Phenomenex Luna 5 μm column, flow 0.8 ml/
minute; UV detection at 240 nm and 300 nm, neg. And
pos. MS detection (150–1500 amu, fast mode); ambient
temperature; gradient made from ACN and aq. 10 mM
ammonium formate pH 9. MS (pos.), MS (neg.) and DAD
information was recorded online. For MS spectra only the
most abundant isotope signal is indicated; for UV spectra,
only signals > 220 nm are indicated
Preparation of compound 38
A solution of 28 g (0.1 mol) hexaethylene glycol, 27.5 g
(0.105 mol) triphenylphosphine and 15.5 g (0.105 mol)
phthalimide in 300 ml THF was treated with 20 g
(0.1 mol) diisopropyl azodicarboxylate. The solution was
stirred 45 min at 20 °C and filtered. The filtrate was evap-
orated and subjected to CC (350 g SiO2) with a DCM /
MeOH gradient affording 18 g 36 as viscous, colorless oil.
This compound was dissolved in 300 ml MeOH, treated
with 15 ml hydrazine monohydrate and kept overnight at
50 °C. The suspension was filtered and evaporated: 11.5 g
37 as colorless oil. This oil was suspended in 75 ml
CHCl3, filtered and evaporated. The residue was dissolved
in 300 ml DCM and treated with 10 g (0.1 mol) TEA and
11 g (0.05 mol) di-tert-butyl dicarbonate. After 30 min at
20 °C, the solution was evaporated, and the residue was
subjected to CC (200 g SiO2) with a DCM / MeOH
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gradient, yielding 15 g (40% overall) of 38 as a viscous, col-
orless oil.
Preparation of compound 39 (= B2)
A suspension of 150 mg (0.375 mmol) compound B1
(synthesised by CISTIM), 150 mg (0.4 mmol) 38 and
190 mg (0.75 mmol) 1,1′-(azodicarbonyl)dipiperidine
in 5 ml THF was heated at 50 °C and then treated
with a solution of 150 mg (0.75 mmol) tributylpho-
sphine in 1 ml THF. After 45 min at 50 °C, the sus-
pension was filtered, and the filtrate was evaporated.
The residue was subjected to CC (6 g SiO2) with a
hexane / EtOAc gradient. The product-containing frac-
tions were evaporated affording 250 mg of a white solid
(containing about 30 wt % reduced 1,1′-(azodicarbonyl)di-
piperidine). Fifty mg of this mixture were subjected to
prep. TLC with EtOAc as eluent. The product-containing
band was scratched off and eluted with EtOAc / MeOH
9:1 yielding 18 mg 39 as a colorless oil.
Preparation of compound 40
At 20 °C, 200 mg of the material obtained above
(containing about 70% 39) were dissolved in 2.5 ml
TFA / H2O 9:1. After 45 min, 10 ml toluene were
added, and the mixture was evaporated. The residue
was subjected to CC (6 g SiO2) with a DCM / MeOH
gradient; after elution of by-products with 4% MeOH,
2% TEA was added to the eluent to elute the prod-
uct. The product-containing fractions were evapo-
rated, giving 125 mg 40 as colourless, viscous oil
(63% yield based on B1).
Preparation of compound 41
A solution of 125 mg (0.19 mmol) 40 and 105 mg
(0.2 mmol) MTX (COOtBu) COOLi in 1.0 ml DMF was
treated with 100 mg (0.22 mmol) BOP. After 30 min at
RT, LC-MS indicated completion of the reaction. The re-
action mixture was diluted with 8 ml MeOH/H2O 1:1
and purified by MPLC (250 ml MeOH / aq. 10 mM
NH3 1:3, 250 ml ACN / aq. 10 mM NH3 4:6, 500 ml
ACN / aq. 10 mM NH3 1:1). The product containing
fractions (analysed by LC-MS) were evaporated,
co-evaporated with MeOH and then with DCM and
dried: 170 mg (78%) product 41 as yellow, solid foam.
LC (10–100% in 15 min): 8.2 min (96%) UV: 230 nm
(max), 260 nm, 305 nm, 375 nm MS (pos): 1150 (M + 1)
MS (neg): no signal detected.
Preparation of fusion compound used for the target
identification screen (alias 42)
Solid 41 (170 mg, 0.145 mmol) was dissolved in 2.0 ml
TFA/H2O 9:1 and stirred 50 min at 20 °C. The reaction
mixture was cooled to 4 °C and neutralised by drop-wise
addition of conc. aq. NH3 solution, diluted with 5 ml
MeOH/H2O 1:1 and purified by MPLC (500 ml MeOH /
aq. 10 mM NH3 1:9, 500 ml ACN / aq. 10 mM NH3 7:3).
The product containing fractions were evaporated, co-evap-
orated with MeOH and dried: 120 mg (75%) of product 42
(REM0044931) as a yellow solid. 1H-NMR (300 MHz,
CD3OD / CDCl3 2:1): LC (10–100% in 15 min): 5.6 min
(98%), UV: 230 nm (max), 260 nm, 305 nm, 375 nm, MS
(neg.): 1092 (M-1), MS (pos): 1094 (M+ 1).
Results
Identification of small molecule modifiers counteracting
mechanisms underlying neurotoxicity in AD
In order to identify new drug targets and therapeutics
underlying AD we implemented a neuronal cell-based
model of Ca2+-driven neurodegeneration. For this rea-
son, we used neuroblastoma cells containing mutant hu-
man tau (TAU-P301L) as these cells were found to be
more susceptible to toxic stimuli compared to control
cells (Additional file 1: Figure S1a). Neurotoxicity in the
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model was induced by incubating the cells with ATRA
[28]. Upon chronic exposure to ATRA a significant in-
crease in toxicity within seven days in culture was con-
sistently detected (Fig. 1a; Additional file 1: Figure S1b).
Quantification of Ca2+ indicator fura-2 fluorescence in
the cells following ATRA challenge (Fig. 1b) revealed a
significant increase in [Ca2+]i concurring with toxicity.
We thus assessed whether the rise in [Ca2+]i levels is
causal to toxicity and restrained Ca2+ influx from the
extracellular environment through silencing STIM1 ex-
pression, an activator of the Orai channels facilitating in-
flux of extracellular Ca2+ into the cytosol. Decreasing
STIM1 expression in these cells led to a robust reduc-
tion of ATRA induced toxicity (Fig. 1c). In addition, isra-
dipine, a voltage-gated Ca2+ channel (VGCC) inhibitor
with neuroprotective potential [29], also rescued cell
death in the model (Additional file 3: Figure S2a). Thus,
ATRA induced toxicity is reduced by lowering [Ca2+]i in
this model.
Deregulated kinase activity has been associated with
neuronal dysfunction in AD. Thus, [Ca2+]i which is a
known regulator of mitogen-activated protein kinase
(MAPK) signalling [30], may thus mechanistically may
underlie the elevated extracellular signal-regulated kinase
(ERK1/2) activity observed in preclinical AD models as
well as patients [31, 32]. We therefore quantified ERK1/2
activity throughout the ATRA incubation period. The first
four days ERK1/2 activity remained relatively low (data not
shown), however, the following days, when toxicity started
to rise, its activation was found to be significantly increased
compared to control conditions (Fig. 1d). To further
validate that MAPK ERK deregulation contributes
ATRA induced cell death, we applied the MEK inhibi-
tor U0126. Indeed, addition of U0126 counteracted
ATRA induced toxicity in a concentration dependent
manner (Additional file 3: Figure S2b). This indicates
that ERK1/2 signalling, likely as a result of deregulated
[Ca2+]i observed in the model, plays an important role
in mediating cell death as a consequence of ATRA
exposure.
Taken together, the model features a rise in [Ca2+]i
and aberrant downstream signalling (at least ERK1/2)
leading to cell death. The assay therefore recapitulates
some key characteristics of AD-like neurotoxicity and
represents an attractive in-vitro system for identifying
mediators and modulators of neurodegeneration.
Subsequently, the model was used to screen library (com-
piled and provided by reMYND NV) of small molecules for
their potential to inhibit toxicity. This led to the identifica-
tion of structurally highly similar tryptamine-derivatives
REM0042826 and REM0043039 (collectively referred to as
REM) (Fig. 1e), which potently and concentration depend-
ently lowered cell loss (Fig. 1f and Additional file 1: Figure
S1) as well as reducing elevated levels of [Ca2+]i (Fig. 1g). In
order to emphasise the relevance of the phenotypic screen-
ing system described above for identifying novel neuropro-
tective compounds, we also tested REM in a more
conventional AD model involving rat hippocampal neurons
challenged with Aβo’s. Incubating the neurons with Aβo’s
resulted in pronounced cell death. However, in the presence
of REM, the soluble Aβo-elicited cytotoxicity was coun-
tered, independently illustrating the compound’s neuropro-
tective activity (Additional file 4: Figure S3). Altogether, we
identified novel compounds that restore Ca2+ homeostasis
through which they appear to convey their protective ef-
fects in cellular models of AD.
Binding of REM in the prenyl-binding pocket of Pde6δ is
required for mitigating toxicity
Following the identification of the REM, we set out to
identify the corresponding target mediating their neuro-
protective effects. To this end we coupled REM to metho-
trexate (resulting in REM0044931, see Methods) and used
it as bait in a yeast-based 3-hybrid system [27] to deter-
mine interacting proteins using a human cDNA expres-
sion library (constructed by Dualsystems Biotech). This
led to the identification of several cDNA fragments encod-
ing (parts of) Pde6δ. We independently confirmed the
interaction of the compound with full length human
Pde6δ in MASPIT [26], a mammalian cell based 3-hybrid
assay, and revealed a concentration-dependent interaction
with a half-maximal concentration for binding of 45 nM
(Fig. 2a). A direct interaction between REM and Pde6δ
was validated further in a cell free context by co-immuno-
precipitation (Fig. 2b).
In order to confirm that Pde6δ mediates the neuropro-
tective properties of REM, we silenced PDE6δ in the tox-
icity cell model (Fig. 2c). Silencing reduced cell death,
indicating that Pde6δ mediates (at least in part) toxicity in
the model. Although the remaining toxicity in silenced
cells was slightly reduced by the compound, an effect
which is presumably due to a residual Pde6δ presence, it
was not decreased below the level obtained with REM in
non-silenced control cells. Thus, the toxicity-mitigating
effect of REM requires the presence of Pde6δ.
To better understand the interaction between REM and
its target we aligned the cDNA’s identified in the three-hy-
brid screens. This revealed that the minimal region of
Pde6δ required for interaction with REM corresponds to a
part of its prenyl-binding pocket (data not shown). The lat-
ter hydrophobic cavity accommodates fatty acid chains of
small GTPases and is necessary to extract and transport
these between cellular membranes [33–35]. In-silico mod-
elling then further elucidated that the identified compounds
align closely with prenyl-chains (Fig. 2d). This common
topology raised the possibility that it was possible for REM
to fit inside Pde6δ’s hydrophobic pocket. Using the cavity’s
position to define the docking search space, we assessed
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Fig. 1 Development of an AD model for identifying neuroprotective compounds. a Toxicity was determined by quantifying LDH release in the
medium in BE (2)-M17 neuroblastoma cells incubated for 7 days with or without ATRA. The ATRA induced toxicity in the cells represents the “toxicity
assay” used in all following experiments (n = 5; +/− ATRA: P < 0.0001; t = 7,346 DF = 8). b Cytosolic Ca2+ levels quantified by Ca2+-indicator Fura-2
fluorescence ratio (340 nm/380 nm) in hTAU-P301L cells after 6 days with and without ATRA treatment in the toxicity assay (n = 3; P = 0.0435; t = 2.915;
DF = 4). c Genetic silencing of STIM1 reduces toxicity in the toxicity assay. # denotes the effect of STIM1 silencing compared to unsilenced cells, *
indicates the effect of ATRA treatment (silencing: P < 0.0001; DF = 1; F (1, 36)=4048; ATRA treatment: P < 0.0001; DF = 1; F (1, 36)=8006; Corrected for
multiple comparison using Tukey’s test: +/−ATRA - silencing: P < 0.0001; q = 132.4; DF = 36; −ATRA +/− silencing: P < 0.0001; q = 20.68; DF
= 36; +/−ATRA + silencing: P < 0.0001; q = 46.53; DF = 36; +ATRA +/− silencing: P < 0.0001; q = 106.6; DF = 36). d Increased MAPK signalling
prior to toxicity measured by western blot in the cells treated with or without ATRA (day 5). Data are normalised to the “control” (−ATRA) condition
(n = 4; P = 0.0322, t = 2.775, DF = 6). A representative immunoblot is shown in the inset next to the graph. e The chemical structure of the REM
compounds. R1 could be either Cl (REM0042826) or F (REM0043039) (Additional file 2: Supplementary Methods). f Concentration-response curves of
ATRA-toxicity reducing effect REM0042826 (EC50 = 12 nM) and REM0043039 (EC50 = 5 nM) in the toxicity assay (n = 7 or 5 for REM0043039 or
REM0042826 respectively). g Concentration-response curve (n = 3) of the cytosolic Ca2+ reducing effect of REM, (EC50 of 3 nM) in the toxicity
assay. The dotted grey line represents the average basal Ca2+ levels of vehicle treated cells in the model (One-way ANOVA, REM treatment:
P = 0.0387; F = 3.386; DF = 5)
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whether REM interacts with the pocket. Validation of the
docking procedure came from re-docking the farnesyl moi-
ety into the Pde6δ structure. The best docked pose showed
a root-mean-square deviation of less than 0.5 Å (all heavy
atoms) compared to the published X-ray farnesyl position
(Additional file 5: Figure S4a). Taken together, docking of
REM revealed that the compound fits well and with high
affinity in this cavity (Fig. 2ef and f).
Closer analysis found that the indole group extends deep
into the pocket overlapping with the dimethylallyl end of
farnesyl and that the indole nitrogen atom is oriented
toward Ile129 and Thr131, creating weak interactions,
while the amide oxygen atom is engaged in a hydrogen
bond with the Arg61 side chain. Furthermore, REM’s
oxazole ring forms a pi-pi stacking with Trp90 and the
di-fluoro phenyl group occupies the highly hydrophobic
entrance of the pocket. The modelling data thus indi-
cate that REM can bind into the prenyl-binding cavity
and as a result may prevent Pde6δ’s prenylated sub-
strates from interacting with it.
Fig. 2 REM bind to the prenyl-binding pocket of Pde6δ. a Concentration-dependent interaction of methotrexate fused REM compound (REM0044931)
to full-length Pde6δ in the mammalian 3-hybrid assay MASPIT (EC50 = 45 nM; n = 3). b Pde6δ-Strep and REM compound interaction assay. Left, schematic
representation: E. coli lysates producing Pde6δ-Strep, E. coli lysates with His-tagged DHFR and 10 μM REM were mixed and subjected to a Strep-Tactin
pull-down. Right, co-precipitation of DHFR-His was assessed by Western analysis. Pull-down with all compounds as described above (lane AS), without
REM-MTX (lane A) or without Pde6δ-Strep (lane B). c Left, genetic silencing of PDE6δ in the toxicity assay in function of increasing concentrations REM
(n = 6). Box on the right, efficiency of silencing validated by Western blot ((representative immunoblots; immunostaining of GAPDH was determined as a
loading control; Pde6δ expression was reduced on average by 88% ± 3%; Average ± SEM) (One-way ANOVA (REM treatment); siNC: P = 0.0002; F = 5.29;
DF = 7; siPDE6δ: n.s.)). d Superimposition of REM compound (purple) and farnesyl (grey). e REM docking into the Pde6δ prenyl-binding pocket showing all
interacting amino acids. In green indicates hydrophobic amino acids, in dark blue positively charged amino acids and in cyan neutral polar amino acids. f
REM docked in Pde6δ’s prenyl-binding pocket (ribbon)
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REM binding to Pde6δ disrupts the interaction with Rap1
GTPase required for lowering [Ca2+]i and toxicity
Since the modelling data indicated that REM might
compete for Pde6δ substrate binding, we set out to iden-
tify such anticipated interactor(s) in an affinity purifica-
tion coupled with mass spectrometry assay [36] (Fig. 3a)
and assessed whether these interactions are impacted by
REM. In absence of the compound, a host of previously
described Pde6δ binding partners were identified, in-
cluding Arl3 and RPGR [33, 37, 38] as well as apparently
novel interactors like Lamin B2 and Fbxo10. Also,
Rab28 and Rap1A representing prenylated GTPases
were found to interact with Pde6δ. Importantly, of all
detected interactions, only the Pde6δ-Rap1A interaction
was significantly and robustly reduced by REM.
Moreover, disruption of the Pde6δ-Rap1A interaction
was found to be specific as the interaction with non-preny-
lated binding partners of Pde6δ such as Arl3 and RPGR,
remained unchanged. In fact, there appears to be further
specificity regarding the nature of the poly-isoprene lipid
group, illustrated by the distinct effects on Pde6δ substrates
Rap1A and Rab28. In the presence of REM, Pde6δ’s inter-
action with geranylgeranylated (C20) Rap1A is inhibited,
contrary to that with farnesylated (C15) Rab28. This select-
ivity of the compound may be a reflection of the intrinsic-
ally higher affinity of Pde6δ towards farnesyl over
Fig. 3 REM reduces toxicity and [Ca2+]i by selectively abrogating the interaction of Rap1 with Pde6δ. a Affinity purification coupled with mass
spectrometry assay to identify interactors associating with Pde6δ in a REM dependent fashion. Signals for each interactor were normalised to the
vehicle condition (n = 3; Treatment: P = 0.01; DF = 1; F (1, 32)=7.508; Rap1A: P < 0.0001; t = 5.284; DF = 32). b Left, the impact of genetic silencing
of RAP1A in the toxicity assay in function of increasing concentrations REM (n = 6). Box at the right, efficiency of silencing validated by Western
analysis (representative immunoblots; immunostaining of GAPDH was determined as a loading control; Rap1A expression was reduced on
average by 66% ± 8%; Average ± SEM). (One-way ANOVA (REM treatment); siNC: P = 0.0004; F = 4.615; DF = 8; siRAP1A: n.s.). c Concentration-
response curve of deltarasin in the toxicity assay (EC50 = 480 nM; n = 3). d The impact of genetic silencing of PDE6δ or RAP1A in the neuroblastoma
cells on cytosolic Ca2+ levels in the toxicity assay in function of increasing REM concentrations (n = 2 per concentration; one representative experiment
of three is shown)
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geranylgeranyl [39]. Thus, the experimental data confirmed
the in-silico docking results and revealed that REM binds
to and occludes Pde6δ’s hydrophobic pocket, preventing
the interaction specifically with a geranylgeranylated sub-
strate which we identified as Rap1A.
From these data we envisaged that the toxicity-lowering
effects of REM are brought about by abrogating the inter-
action of Rap1A with Pde6δ. To test this hypothesis, we
assessed whether toxicity in our model required Rap1A.
Silencing RAP1A completely prevented any REM com-
pound induced decrease in toxicity (Fig. 3b), indicating
that REM requires Rap1A for its effect. We independently
confirmed this result by using deltarasin, a compound
structurally unrelated to REM, which also binds in Pde6δ’s
prenyl-binding pocket [40] and, similarly to REM, showed
a trend towards counteracting cell-death in our model of
neurotoxicity (Fig. 3c).
Having established that REM targets the Rap1-Pde6δ
interaction for lowering neuronal toxicity in our model,
we tested whether decreasing elevated [Ca2+]i requires
both proteins. To this end, we measured [Ca2+]i levels in
Pde6δ and Rap1A silenced cells in function of REM
treatment in the neurotoxicity model. This revealed that
silencing of both PDE6δ and RAP1A reduced [Ca2+]i
levels to a similar extent (Fig. 3d), indicating that both
Pde6δ and Rap1A are required for elevated [Ca2+]i in
the model. Furthermore, in both Pde6δ and Rap1A si-
lenced cells, the already low levels of [Ca2+]i were not re-
duced below the levels recorded in non-silenced cells by
REM. Thus, the REM mediated decrease of [Ca2+]i in
the model is, like toxicity, dependent on Pde6δ and
Rap1A.
Taken together, we revealed geranylgeranylated Rap1A
as a novel substrate of Pde6δ’s prenyl-binding pocket
and that this interaction is involved in Ca2+ dyshomeos-
tasis and associated cytotoxicity.
Disruption of the Pde6δ-Rap1 interaction has distinct
effects on spatially discrete Rap1-functions
Pde6δ is known to act as a cytosolic chaperone control-
ling the subcellular membrane localisation (and thereby
their function) of prenylated substrates [25, 34, 37, 41],
such as Rap1. In particular, Rap1 was shown to regulate
signalling of MAPK-ERK1/2 at spatially discrete subcel-
lular locations [42–46]. In resting neurons for instance,
basal levels of Ca2+ and cAMP [47] control a mem-
brane pool of Rap1-ERK1/2, which phosphorylates (in-
activates) protein Kv4.2, the main A-type K+ channel
driving the fast transient outward K+ current (IA) in-
volved in action potential AHP and repolarisation in
pyramidal neurons [48]. On the other hand, upon de-
polarisation a different subcellular pool of Rap1-ERK1/
2 has been implicated in signalling towards nuclear tar-
gets mediating gene transcription [49], whereas an
exclusively intracellular pool of mGluR-Rap1-ERK1/2
mediates the internalisation of surface AMPA receptors
during LTD [50–52].
Given that Pde6δ regulates the subcellular membrane
localisation of prenylated substrates, we hypothesised
that Pde6δ mediated control over Rap1 functions at
spatially discrete pools specifies its signalling outcome.
Accordingly, disruption of the Rap1-Pde6δ interaction
by REM should alter activity of distinct ERK1/2 signal-
ling pathways. To test this hypothesis, we assessed basal
and mGluR driven Rap1-ERK1/2 activity.
As shown previously in the toxicity model, basal ERK1/
2 activity was found to be strongly increased under condi-
tions of cell death (Fig. 4a). However, in the presence of
REM, this ERK1/2 over-activation was strongly reduced
(Fig. 4a). Also, in hippocampal neurons, where synaptic
activity was eliminated using the Na+ channel blocker
TTX, REM treatment led to a reduction in basal ERK1/2
activity (Fig. 4b). Conversely, upon stimulation with the
selective group 1 mGluR agonist DHPG the fold Rap1-
ERK1/2 activation in cells incubated with REM was in-
creased compared to vehicle treated cells (Fig. 4b).
Collectively, these results indicate that the basal activity of
Rap1-ERK1/2 signalling in resting cells, which is consid-
ered to represent the membrane-associated pool [49], is
decreased by REM, while activation of an intracellular
DHPG responsive pool [53] of Rap1-ERK1/2 signalling is
increased.
We then tested whether such REM-induced changes on
different pools of Rap1-ERK1/2 resulted in functional
changes in an AD model. Previous studies have shown
that lowering basal Rap1-ERK1/2 signalling reduces the
phosphorylation of plasma membrane Kv4.2 channels and
thereby increases neuronal repolarisation [49, 54]. This
regulation appears highly relevant for AD because in Aβ1–
42 exposed hippocampal primary neurons and in numer-
ous human transgenic APP mouse models the activity of
Kv4.2 is reduced [10, 55]. As a result of this, transgenic
APP models were shown to feature an A-type K+
channel-deficiency driving neuronal hyperactivity [10, 56]
and therefore we anticipated REM to mitigate this pheno-
type. To test this, we quantified the IA in function of REM
treatment. Hippocampal CA1 somatic voltage-clamp re-
cordings were performed in acute slices excised from hu-
man transgenic APP[V717I] (hAPP) [21] mice orally
administered with vehicle or a single dose of REM at
30 mg/kg. The recorded IA current (as isolated by subtrac-
tion of the 4-AP insensitive from the total K+ current
(Additional file 6: Figure S5a)) was significantly increased
at higher depolarising pulses by REM compared to the ve-
hicle group (Fig. 4c).
Furthermore, to test the impact of REM on neuronal
repolarisation, single action potentials (AP) were assessed
by somatic patch-clamp of hippocampal CA1 pyramidal
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Fig. 4 REM modulates spatially discrete Rap1-ERK1/2 signalling processes. a Western blot analysis of ERK1/2 phosphorylation in neuroblastoma cells after
7 days with or without ATRA toxicity challenge and with or without (0.25 μM) REM (n = 3; Vehicle +/− ATRA: P = 0.0066; t = 5.191; DF = 4; Vehicle/REM+
ATRA: P = 0.0052; t = 5.55; DF = 4). Representative Western blots are shown in inset above the graph. bWestern blot analysis of ERK1/2 phosphorylation
ratio to total ERK1/2 in DIV ≥19 mouse primary hippocampal neurons treated with or without 50 μM DHPG and REM/Vehicle as indicated (n = 6; ordinary
two-way ANOVA followed by Tukey’s multiple comparison test; P < 0,0001; DF = 1; F (1, 20) = 27,41; vehicle +/− DHPG: P = 0,0248; q = 4,431; DF = 20; REM
+/− DHPG: P < 0.0001; q = 14,9; DF = 20; vehicle/REM - DHPG: P = 0,0107; q = 4,975; DF = 20; vehicle/REM+DHPG: p = 0,0047; q = 5,497; DF = 20).
Representative Western blot images are shown in insets above graph. c K+ current analysis in hAPP mice treated with a single dose of REM or vehicle
show that application of REM increases the IA contribution at higher membrane potentials (50–60 mV) (n = 7 per condition; RM-two way ANOVA
Interaction: P = 0.056; DF = 15; F(15,180) = 1.691; Sidak’s multiple comparison: membrane potential 50 mV Vehicle/REM: P = 0.0326; t = 3.122; DF = 192;
membrane potential 60 mV Vehicle/REM: P = 0.0130; t = 3.401; DF = 192). d Analysis of AHP amplitudes in function of REM treatment obtained by
longitudinal somatic recordings of single APs in WT and hAPP slices that were incubated with vehicle or 2 μM REM. (Two-way ANOVA repeated measures,
followed by Sidak’s multiple comparison test; n = 7 WT mice or n = 8 hAPP mice; Treatment: P = 0.0015; DF = 1; F (1, 13)=15.91; Genotype: P = 0.0279;
DF = 1; F (1, 13)=6.127; WT/APP + Vehicle: P = 0.0376; t = 2.502; DF = 26; hAPP + Vehicle/REM: P = 0.006; t = 3.635; DF = 13.) Examples of recorded traces are
shown above the graph. e CA3-CA1 LTD: quantification of fEPSP slopes from hippocampal slices. Slices were continuously perfused with artificial CSF
containing vehicle or REM for (at least) one hour prior to (pre-incubation), as well as during and after the addition of DHPG (two-way ANOVA repeated
measures; n = 6 mice per condition; Treatment: P = 0.0032; DF = 1; F (1, 10)=14.91). Example traces are shown above the graph. f Graph shows the
summary of mean fEPSP slopes during the 41–60 min interval from d (n = 6 mice per condition; P = 0.0008; t = 4.725; DF = 10)
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neurons from acute brain slices of hAPP and WT mice.
These recordings revealed that the AHP amplitude was
significantly decreased in hAPP mice compared to WT
mice, (Fig. 4d). After these baseline measurements, treat-
ment of the same hAPP slices with REM significantly in-
creased (normalised) the AHP amplitude (Fig. 4d). No
significant impact of REM was observed on other AP pa-
rameters in hAPP slices (data not shown). Since Kv4.2
plays a key role in regulating dendritic AP shape and
propagation, we also assessed CA1 dendritic single AP’s
(recorded > 200 μm from soma) in hAPP acute brain
slices. These recordings likewise revealed that REM ro-
bustly increased the AHP amplitude (Additional file 6:
Figure S5b).
Collectively, these data indicate that REM predomin-
antly facilitates the K+ channel driven component of
AP’s. This is consistent with the hypothesis that lowering
basal Rap1-ERK1/2 signalling by REM treatment in-
creases K+ channel activity and neuronal repolarisation.
In addition, we assessed the functional impact of a
REM-driven increase in intracellular mGluR5-Rap1-ERK1/
2 signalling (Fig. 4b) and ensuing LTD. As expected, DHPG
induced a significant and robust decrease in fEPSP slopes
compared to baseline, indicating a depression of synaptic
efficacy through AMPA receptor removal (Fig. 4d) [57].
Pre-incubation with REM led to a significantly greater re-
duction in fEPSP slopes 40 min after the induction
compared to vehicle (Fig. 4d and e), revealing that mGluR
driven LTD is enhanced by the compound. Thus, these data
indicate that Pde6δ controls intracellular Rap1-ERK1/2
signalling regulating synaptic plasticity.
Altogether, we demonstrated that Pde6δ modifies the
outcome of different subcellular Rap1-ERK1/2 signalling
pathways. Accordingly, REM, by neutralising Pde6δ’s con-
trol over Rap1, reduces basal Rap1-ERK1/2 activity in rest-
ing neurons, which enhances the K+ channel driven
component of AP’s; while increasing mGluR-Rap1-ERK1/
2 signalling, leading to greater synaptic depression.
Abrogation of the Rap1-Pde6δ interaction by REM
reduces VGCC activity
Previous studies demonstrated that Rap1-ERK1/2 sig-
nalling regulates the surface expression and conse-
quently the activity of L-type VGCC [58]. We therefore
tested whether inhibiting Pde6δ’s control over Rap1 al-
ters the activity of VGCC’s, measuring Ca2+ influx after
depolarisation induced by high extracellular K+ in func-
tion of REM treatment. Here, the addition of potassium
chloride (KCl) to the extracellular medium produced a
concentration-dependent increase in [Ca2+]i (Fig. 5a).
This Ca2+ influx was shown to be in part mediated by
L-type VGCC’s, since the influx was reduced by ap-
proximately 50% in the presence of L-type channel spe-
cific inhibitor nifedipine (Fig. 5b). Incubation with REM
significantly lowered Ca2+ influx only at KCl concentra-
tions above 25 mM (Fig. 5a), indicating that REM specific-
ally inhibits VGCC’s that are active during relatively
strong depolarisations such as L-type channels [59].
Co-application of nifedipine together with REM pro-
duced no additional inhibition compared to nifedipine
alone, indicating that the compound acts on nifedipine sen-
sitive channels (Fig. 5b and Additional file 7: Figure S6).
Thus these data show that Rap1-ERK1/2 signalling controls
VGCC surface activity and consequently neurotransmitter
release upon depolarisation [58]. Further we show that
Pde6δ modifies Rap1 mediated VGCC activity.
Inhibition of the Pde6δ-Rap1 interaction with REM
restores spike frequency adaptation in hAPP mice
Our data thus far demonstrated that REM facilitates neur-
onal repolarisation, decreases synaptic efficacy and lowers
VGCC activity, each process on its own geared towards
restraining neuronal excitability under conditions of strong
stimulation. We therefore assessed the neuronal firing rate
Fig. 5 REM represses VGCC activity in primary hippocampal neuron
cultures. a Quantification of [Ca2+]i influx using Ca
2+ indicator Fura-2 after
KCl instigated depolarisation at increasing concentrations in function of
1.5 μM REM treatment. Graphs represent the normalised mean Area’s
Under the Curve’s (AUC) over a 4 min period after the addition of KCl
(n = 3; Treatment: P = 0.0015; DF = 1; F (1, 20)=13.47; KCl concentration:
P < 0.0001; DF = 4; F (4, 20)= 68.45; Multiple comparisons test: 45 mM KCl
Vehicle/REM: P = 0.0454; t = 2.881; DF = 20). b AUC’s are determined as in
(a) after exposure to 45 mM KCl in presence or absence of 12.5 μM
nifedipine as indicated. A representative Ca2+ trace (+/−REM) is depicted
in the small inset next to the graph. (n = 5; REM Treatment: P = 0.0003;
DF = 1; F (1, 16)=20.87; +/− Nifedipine: P < 0.0001; DF = 1; F (1, 16)=60.32;
Interaction: P = 0.008; DF = 1; F(1.16) = 9.156; Multiple comparisons test:
Vehicle/REM – nifedipine: P = 0.0004; t = 5.37; DF = 16; Vehicle +/−
nifedipine: P < 0.0001; t = 7.631; DF = 16; REM +/− nifedipine: P = 0.0241;
t = 3.352; DF = 16)
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in mouse hippocampal CA1pyramidal cells by apical den-
dritic current-clamp. Thus, in an initial experiment we set
out to compare WT mice with their hAPP transgenic coun-
terparts. The results show that in WT mice, the firing rate
increased with each current step intensity until 250 pA,
after which the firing frequency started to decline. This de-
cline at high depolarising currents indicates a functional
spike frequency adaptation process, a natural safety mech-
anism protecting neurons from overstimulation. Contrary
to what was observed in WT cells, neurons from hAPP
mice did not demonstrate a decrease in firing frequency at
depolarising currents above 250 pA, meaning that mecha-
nisms underlying spike frequency adaptation in these neu-
rons are dysfunctional (Fig. 6a).
Having shown that overexpression of mutant hAPP led
to enhanced neuronal activity, we conducted a second ex-
periment to assess the impact of REM on the neuronal
firing rates in these mice. Application of REM restored
spike frequency adaptation in hAPP mice as opposed to
vehicle treatment (Fig. 6b).It has to be noted however that
the addition of the vehicle DMSO led to an overall in-
crease in firing rate, an effect that has been previously
documented [60, 61]. This action of DMSO is further sup-
ported by the lack of action potentials generated at the
lowest injected current (50 pA) in absence of vehicle (Fig.
6a) contrary to their presence following DMSO treatment
(Fig. 6b). Nevertheless, regardless of this DMSO effect, the
spike frequency adaptation process in hAPP mice was re-
stored by REM treatment.
In-depth analysis of action potentials evoked at the first
depolarisation current (50 pA) revealed a significant in-
crease in the AHP amplitude in hAPP neurons treated
with REM (Fig. 6c) confirming the single AP findings.
Altogether, our data demonstrate that REM normalises
Fig. 6 hAPP deficit in spike frequency adaptation is rescued by REM. a Dendritic firing rate of hippocampal CA1 pyramidal neurons in WT and hAPP
slices in response to increasing depolarising step current injections (50–450 pA; n = 12 mice per genotype; repeated measures two-way ANOVA:
Interaction: P = 0.0006; DF = 8; F(8,176) = 3.649; Sidak’s multiple comparison: 400 pA: P = 0.0218; t = 3.069; DF = 198; 450 pA: P = 0.0071; t = 3.41; DF =
189). b Dendritic firing rate of hippocampal CA1 pyramidal neurons in WT and hAPP slices perfused with either vehicle or 2 μM REM in response to
depolarising step current step injections (50–450 pA). (Vehicle: n = 12 mice; REM: n = 15 mice; repeated measures two-way ANOVA: Interaction: P <
0.0001; DF = 8; F(8,200) = 5.082; Sidak’s multiple comparison: 400 pA: P = 0.0168; t = 3.146; DF = 225; 450 pA: P = 0.0079; t = 3.372; DF = 225). Note that
the overall firing rates were increased in the second experiment (b) compared to the first one (a). This is likely due to the addition of the vehicle DMSO
which was shown previously to enhance neuronal activity [60, 61]. c Dendritic AHP amplitude in CA1 neurons in response to the first depolarising
current that induced an AP in hAPP slices with or without REM (Vehicle: n = 12 mice; REM: n = 16 mice; P = 0.0128; t = 2.673; DF = 26)
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spike frequency adaptation in hAPP CA1 neurons and in-
creases their repolarisation as evidenced by enhanced
AHP.
Modulation of the Pde6δ-Rap1 interaction and ERK1/2
signalling by REM decreases phosphorylation of tau and
rescues behavioural deficits in different mouse models for AD
We showed earlier that abrogation of the Pde6δ-Rap1
interaction by REM reduced [Ca2+]i and ERK1/2 signalling
in resting neurons. Since MAPK are important Tau kinases
involved in hyperphosphorylation of the protein in an AD
context, REM treatment is expected to lower pathological
Tau phosphorylation. Hence, in-vivo efficacy of REM was
assessed in hAPP*PS1 transgenic mice [22] and two differ-
ent hTAU transgenic mouse strains [62, 63]. Following two
weeks sc administration of REM to hAPP*PS1 mice, West-
ern blot analysis of brain extracts revealed a significant de-
crease in ERK1/2 activity (Fig. 7a), similar to the in-cellulo
observations presented earlier (Fig. 4a). Moreover, patho-
logical phosphorylation of endogenous Tau on different epi-
topes was reduced (pS262 epitope; Fig. 7b; AT8, pT231 and
AD2 data not shown). Similarly, REM treatment of
hTAU-P301L or hTAU-R406W transgenic mice resulted in
a significant decrease in the phosphorylation of different
epitopes of Tau (pS626-Tau, hTau-P301L: Fig. 7c; pS202
and pT205, hTau-R406W: Additional file 8: Figure S7a). No
impact was observed on total levels of Tau protein. As such,
it is reasonable to assume that, since MAPK’s are known to
be involved in Tau phosphorylation [31], the reduction of
the latter is a downstream effect of REM’s action on ERK.
Nevertheless, we cannot exclude the contribution of other
Ca2+-dependent Tau kinases at this point.
Finally, we set-out to assess cognitive deficits in AD mice
in function of REM treatment. To this end, hAPP and WT
mice were tested in a MWM paradigm to assess (hippo-
campal based) spatial learning and memory after chronic
REM or vehicle treatment. Following four days of training,
in which the REM treated hAPP mice showed a reduced
escape latency (Fig. 7d) and search path (Additional file 9:
Figure S8a). During the probe task on day five, REM treated
hAPP mice demonstrated a fully normalised cognitive per-
formance, similar to that of WT mice (Fig. 7e), as opposed
to the vehicle treated ones. After completion of the probe
test, pharmacologically relevant exposure of REM in the
brain of treated animals was confirmed by liquid
chromatography-tandem mass spectrometry (Additional
file 9: Figure S8b). Furthermore, although no MWM-based
learning deficit was observed in R406W-Tau mice com-
pared to WT mice (data not shown), the transgenic mice
showed a significantly reduced mobility (swim speed),
which may represent a motoric deficit observed in most
transgenic Tau models as a consequence of Tau pathology
in the hind brain. This motoric deficit was fully normalised
after a four weeks treatment with REM (Additional file 8:
Figure S7b). In addition, neither short-, nor long-term treat-
ment with REM at the predetermined effective dose led to
any side effects in the mice.
Altogether, these data demonstrate that, by modula-
tion of the Pde6δ-Rap1 interaction, REM treatment re-
duces phosphorylation of protein Tau and rescues
behavioural deficits in different AD-like mouse models.
Discussion
We report the development of a cell-based assay of
neuronal degeneration featuring elevated levels of [Ca2+]i,
deregulation of intracellular signalling and cytotoxicity. As
such the model recapitulates key aspects of neurodegener-
ation in AD and represents a promising system for asses-
sing underlying disease mechanisms and for identifying
new therapies. To this end we have discovered novel com-
pounds (REM), which selectively abrogate the binding of
Pde6δ to small GTPase Rap1, thus representing a valuable
pharmacological tool to study this interaction in more de-
tail. Analysis of REM activity revealed that its target
Pde6δ -by controlling Rap1- impacts Ca2+ homeostasis,
plasticity and excitability, processes fundamentally under-
lying neuronal function and survival. Accordingly, nor-
malising these processes by REM treatment mitigates
neuronal toxicity, reduces in-vivo Tau phosphorylation
and improves cognitive performance in animal models of
AD.
Pde6δ as a GDI-like solubilisation factor facilitates
non-vesicular inter-membrane transport of prenylated
proteins [64]. As such, Pde6δ ensures the correct
spatial organisation of cargo proteins for interaction
with their respective effectors and/or modulators and
thus determines the functional outcome of their signal-
ling [25, 41]. In contrast to what the somewhat mis-
leading name suggest, Pde6δ has no phosphodiesterase
activity but participates in intracellular trafficking of
cognate substrates and is more appropriately coined
prenyl-binding protein δ (PrBP/δ) [64]. We here pro-
vide further evidence that Pde6δ interacts with Rap1
via its prenyl-binding pocket, confirming earlier find-
ings [35]. In case of Ras, Pde6δ was shown to facilitate
shuttling between different membrane locations in the
cell by shielding the GTPase’s prenyl-chain from the
hydrophilic cytosol in its hydrophobic pocket [25, 41].
We therefore propose that, like for Ras, Pde6δ mediates
the inter-membrane transport of Rap1 determining its
subcellular distribution and consequently its function
(Fig. 8).
According to this model, Pde6δ driven transport
would enhance Rap1 enrichment at membranes des-
tined for the PM (Fig. 8). The mechanism of Rap1 re-
moval from the PM remains to be determined.
Nevertheless, it seems reasonable to assume that it,
like for Ras, follows endocytosis [25]. Thus, we
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envisage that under conditions of elevated neuronal
activity and concomitant high rate of endocytosis,
transport of Rap1 towards intracellular membranes is
enhanced. In other words, in active neurons Rap1 is
removed from the PM and concentrated on intracel-
lular membranes. This relocalisation of Rap1 then
reconfigures its functions towards more efficient re-
duction of neuronal excitability. The endomembrane
Fig. 7 REM treatment reduces ERK1/2 signalling, Tau phosphorylation and cognitive impairments in mouse models of AD. a Western blot analysis
quantifying p-ERK1/2 ratio to total ERK1/2 (n = 6 vehicle or 5 REM treated mice; P = 0.0220; t = 2.763; DF = 9) or b phosphorylated Tau at epitope:
pS262 ratio to total tau (Vehicle: n = 4 mice; REM: n = 5 mice; P = 0.0007; t = 5.735; DF = 7) in cortex of transgenic hAPP*PS1 mice treated for
2 weeks with vehicle or REM0043039. Representative immunoblots are shown in inset above the graph. c REM significantly decreases pathological tau
phosphorylation on epitope S262 compared to total tau also in the brainstem of tau P301L transgenic mice (n = 9 vehicle and 13 REM treated mice;
P = 0.0217; t = 2.491; DF = 20). d Escape latency during MWM training comparing WT to hAPP mice with or without REM (n = 12 mice per condition; t-
test: WT Vehicle/hAPP Vehicle: day 2 P = 0.0083; t = 2.901; DF = 22; day 3 P = 0.0153; t = 2.629; DF = 22; day 4 P = 0.00431; t = 3.183; DF = 22; hAPP
Vehicle/REM: day 4 P = 0.056; t = 2.015; DF = 22; WT Vehicle/hAPP REM: day 1(b-d) P = 0.034; t = 2.256; DF = 22; day 2 P = 0.0264; t = 2.381; DF = 22 e
Graphs showing the annulus crossing index (ACI) representing the number of crossings over the platform site in the target area adjusted for crossings
over corresponding areas in other quadrants during the probe test (n = 12 mice per condition; ACI: Vehicle WT/ Vehicle hAPP: P = 0.0069; t = 2.98; DF
= 22; hAPP Vehicle/REM: P = 0.0098; t = 2.829; DF = 22)). (One data-point from hAPP vehicle group is below 0 and is included in the analysis but not
shown in the graph)
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directed transport of Rap1 on the other hand is coun-
tered by Pde6δ, which actively enhances the small
GTPase’s recycling to the PM. REM antagonises this
function of Pde6δ and thereby increases Rap1 on
endomembranes at the expense of a PM localised
pool, gearing the small GTPase’s functions towards
restraining neuronal excitability. Indeed, following
high stimulation (electrically or chemically), REM,
through blockage of Pde6δ mediated Rap1 recycling,
decreases Ca2+ influx and excessive neuronal activity
(Fig. 8).
Taken together, the subcellular membrane distribution
of Rap1 may represent a dynamic auto-regulatory system
containing neuronal excitability within physiological
limits. During excessive stimulation such control would
prevent neuronal hyperactivity and associated excitotoxi-
city, whereas at the same time keeping neurons sensitive
for activation following less strong stimulations. Such a
mechanism does not necessarily imply that Pde6δ-Rap1
functionality is altered in or causal to AD. However, under
conditions of neuronal hyperexcitability, such as occurring
during AD, REM would simply gear Rap1-ERK signalling
towards a reduction of excessive activity.
Considering that neuronal activity is closely associated
with Aβ production as well as its release and thereby aggre-
gation and spread [65]; we anticipate that REM treatment,
by mitigating neuronal hyperactivity, has beneficial effects
on the amyloid burden. Although we have not yet ad-
dressed this aspect of REM action, it remains an interesting
possibility to be explored in future studies.
Moreover, hyperexcitability underlies the susceptibility
of hAPP mice to suffer from epileptic seizures [66], a
phenomenon which is also observed in AD patients [20].
Here we show that REM by abrogating the Rap1-Pde6δ
interaction can normalise neuronal excitability in hAPP
mice. This outcome is not unexpected, since many Rap1
functions affected by REM treatment also represent
major target classes for known anti-epileptic drugs [67],
e.g. voltage-dependent Ca2+ and K+ channels and iono-
tropic glutamate AMPA receptor. Moreover, Kv4.2, the
main A-type K+ channel, appears to be highly involved
in the most prevalent form of epilepsy in adults, namely
temporal lobe epilepsy [68] and experimental models
thereof [69]. We therefore envisage that reducing neur-
onal hyperexcitability by inhibiting the interaction be-
tween Pde6δ and Rap1 has therapeutic potential not
only in AD, but also seizure disorders such as epilepsy.
Along the same lines and, an intracellular pool of Rap1
was previously shown to control the surface expression and
therefore activity of the inhibitory neurotransmitter recep-
tor gamma-aminobutyric acid receptor B (GABAB) [70].
Accordingly, we anticipate that increasing Rap1 on endo-
membranes by REM promotes GABAB surface expression,
providing an additional mechanism of controlling neuronal
activity (Fig. 8). As such, it would be interesting to evaluate
such a REM effect in follow-up studies.
As discussed above, Rap1-ERK1/2 signalling controls a
host of spatially discrete processes underlying neuronal
function and survival. Hence under pathological condi-
tions, where cytosolic Ca2+ levels are chronically ele-
vated, the ensuing inappropriate activation of basal
Rap1-ERK1/2 may lead to a reduction in Kv4.2 activity
[49] and thus contribute to the neuronal hyperexcitabil-
ity observed in the AD models [10, 19]. In agreement
with this notion, we showed that REM diminishes basal
Ca2+ driven Rap1-ERK1/2 signalling originating at the
Fig. 8 Model illustrating how Pde6δ links different pools of Rap1 to Ca2+ homeostasis, neuronal excitability, cognition and neuronal survival. The
Rap1-ERK1/2 cascade emanating from endomembranes represses VGCC and AMPA-R but increases GABAB receptor activity, thus favouring a
reduction in neuronal activity. On the other hand, a plasma membrane associated pool of basal Rap1-ERK1/2 activity inhibits Kv4.2 channels,
which promotes neuronal activity. Assuming that like for Ras [41], removal of Rap1 from the plasma membrane is endocytosis dependent,
neuronal activity coinciding with endocytosis will redistribute Rap1 towards endomembranes. This Rap1 redistribution is geared towards lowering
neuronal excitability, it could represent a natural feedback control to keep neuronal activity and VGCC mediated Ca2+ influx within certain limits
and protecting neurons. Rap1 recycling from endomembranes to the plasma membrane is facilitated by Pde6δ. Thus, inhibition of Rap1 plasma
membrane recycling by REM augments the small GTPase’s presence and activity at endomembranes, while depleting it from the plasma
membrane. As a result, under conditions of persistent excessive neuronal activity (such as in AD and epilepsy), REM rearranges the different pools
of Rap1 towards restraining Ca2+ influx and neuronal excitability, resulting in neuroprotection. (In blue: Rap1-ERK1/2 actions at different
membranes; orange arrows indicate Rap1-ERK1/2 functions altered by REM)
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PM and thereby restores AP repolarisation and the AP
firing pattern in AD models possibly by increasing the
IA–type K
+ current. In addition, REM prevented Ca2+ in-
duced chronic ERK1/2 activation, a process which can
induce apoptosis [71]. Accordingly, we show that down-
regulating basal Rap1-ERK1/2 activity, by inhibiting the
Pde6δ-Rap1 interaction, is neuroprotective in models of
AD. This is in agreement with previous findings where
more general ERK1/2 inhibition approaches conferred
neuroprotection [72–75].
Conclusion
The data presented here indicate that Pde6δ is an im-
portant regulator of Rap1-ERK1/2 signalling by control-
ling the latter’s spatial organisation in the cell.
Consequently, the newly identified neuroprotective REM
compounds, by targeting Pde6δ mediated Rap1
inter-membrane shuttling, restrains critical aspects of
neuronal functionality, including Ca2+ influx and excit-
ability, which ultimately improve neuronal health and
survival under conditions of excessive stimulation. Thus,
targeting Pde6δ has promising therapeutic potential for
disorders characterised by neuronal hyperactivity, such
as AD and epilepsy.
Additional files
Additional file 1: Figure S1. ATRA induced cell death in the model is
enhanced by expression of a cDNA encoding mutant human Tau and is
prevented by REM. a Left: Western blot analysis confirmed successful tau
overexpression (approximately 2-fold) in neuroblastoma cells containing
the hTAU-P301L plasmid. Right: Toxicity was determined by quantifying
LDH release in the medium in BE (2)-M17 neuroblastoma cells with
(hTAU-P301L) and without (Control) expression of a cDNA encoding
hTAUP301L incubated for 7 days with or without ATRA. The ATRA
induced toxicity in hTAU-P301L cells represents the “toxicity assay” used
in all following experiments (two-way ANOVA: +/− ATRA: P < 0.0001, F(1,
36)=4276, DF = 1; +/− hTAU-P301L: P < 0.0001, F (1, 36)=255.3, DF = 1;
Sidak’s multiple comparison test: control +/− ATRA: P < 0.0001, t = 27.54,
DF = 36; hTAU-P301L +/− ATRA: P < 0.0001, t = 64.93, DF = 36; n = 10). #
denotes the effect of hTAU-P301L expression silencing compared to
control cells, * indicates the effect of ATRA treatment. b Representative
images of neuroblastoma cells exposed to ATRA for six days treated with
either REM or vehicle. c Treating hTAU-P301L cells in the toxicity assay
with tau aggregation inhibitior methylthioninium rescues cell death
((EC50 = 23 nM; n = 3) One-way ANOVA, Methylthioninium treatment:
P < 0.0001, F = 109.7, DF = 4). (TIF 1286 kb)
Additional file 2: Supplementary Methods [76, 77]. (DOCX 17 kb)
Additional file 3: Figure S2. Reduction in Ca2+ influx through VGCCs
reduces ATRA induced toxicity. a The effect of isradipine (VGCC inhibitor)
in the toxicity assay (EC50 = 971 nM; n = 2). b The effect of U0126 (ERK1/2
kinase kinase (MEK) inhibitor) in the toxicity assay ((EC50 = 55.88 nM; n =
4) One-way ANOVA, U0126 treatment: P < 0.0001, F = 95.21, DF = 5). (TIF
110 kb)
Additional file 4: Figure S3. REM rescues ADDL induced cytotoxicity in
primary hippocampal neurons. Viability assessment using live (yellow)/
dead (purple) assay (representative pictures below the graphs – i, Control;
ii, vehicle; iii, REM) of rat primary hippocampal neurons (Additional file 2:
Supplementary Methods) exposed for 24 h to 1 μM ADDL’s treated
with vehicle or 0.25 μM REM0043039 ((n = 3) Control/Vehicle: p =
0.0175, t = 3.9, DF = 4; Vehicle/REM: P = 0.0208,
t = 3.704, DF = 4). (TIF 2806 kb)
Additional file 5: Figure S4. The farnesyl group of Rheb fits into
Pde6δ’s hydrophobic pocket. a Rheb’s farnesyl moiety sequestered in
Pde6δ internal hydrophobic cavity as solved in X-ray crystal structure.
Pde6δ shown in ribbon (left) or solid surface (right), and farnesyl moiety
fused to terminal cysteine shown in stick bonds. b Superimposition of
the farnesyl moiety (purple) and farnesyl group as solved in the crystal
structure (grey). (TIF 1245 kb)
Additional file 6: Figure S5. REM increases somatic and dendritic
action potential AHP in hAPP brain slices. a K+ current analysis: left graph
shows the total K+ current; right graph shows the 4-AP (IA channel
blocker) insensitive current (n = 7 mice per condition; RM-two way
ANOVA 4-AP insensitive current amplitude: Interaction: P = 0.0294;
F(15,180) = 1.865; DF = 15; Sidak’s multiple comparison test: 60 mV: P =
0.0496; t = 2.988; DF = 192; 70 mV: P = 0.0088; t = 3.512; DF = 192). b
Dendritic single AP parameters in hAPP brain slices after at least one
hour vehicle or REM incubation; example traces are shown in the insets
next to the graphs. (n = 8 mice per condition; AHP amplitude: P =
0.0003; t = 4.816; DF = 14; AP decay slope: P = 0.0317; t = 2.387; DF =
14). (TIF 263 kb)
Additional file 7: Figure S6. REM decreases KCl depolarisation induced
Ca2+ influx by modulation of L-type channels. Summary of Fura-2 fluorescence
traces (ratio 340/380 nm over time) after normalising to the mean of the first
minute “baseline” recording. (+ nifedipine: n = 8; − nifedipine n = 16).
(TIF 197 kb)
Additional file 8: Figure S7. REM reduces behaviour deficits and
phosphorylated Tau in R406W mice. a Western blot analysis showing the
ratio of phosphorylated Tau on epitope AT8 (pS202, pT205) to total Tau
in cortex of R406W transgenic mice treated with either vehicle or REM
subcutanously for 4 weeks. Examples of the immunoblots are shown
above the graph. (n = 8 or 9 vehicle or REM treated respectively; P =
0,0328; t = 2,324; DF = 17). b Average velocity of R406W Tau transgenic
mice during a MWM test after 4 weeks treatment with REM. (n = 16 or 18
or 17 WT + Vehicle or R406W + Vehicle or R406W + REM respectively; WT
+ Vehicle/R406W + Vehicle: P = 0,0033; t = 3,181; DF = 32; R406W + REM/
+Vehicle: P = 0,0307; t = 2,258; DF = 33). (TIF 160 kb)
Additional file 9: Figure S8. REM reaches effective concentrations in
brains of hAPP mice and improves their ability to learn during a MWM
test. a Search path length during the 4 training days in a MWM setting.
(n = 12 mice per condition; multiple t-test: WT/hAPP Vehicle day 4: P =
0.033; t = 2.277; DF = 22; hAPP Vehicle/REM day 4: P = 0.05; t = 2.072; DF
= 22). b Brain exposure levels of REM in hAPP mice 3 h post last dose.
(TIF 142 kb)
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transgenic APP-V717I; hAPP*PS1: Human mutant transgenic APP-V717I*PS1-
A246E; IA: Fast transient outward K
+ current; K+: Potassium; KCl: Potassium
chloride; LDH: Lactate dehydrogenase; LTD: Long-term depression; MAPK: Mitogen-
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saline; TTX: Tetrodotoxin; WT: Wild-type
Acknowledgements
The authors are indebted to Dr. Michael Kreutz for critically reading the manuscript.
Funding
This work was supported by the People Program (Marie Curie Actions) of the
European Union’s Seventh Framework Program FP7/2007–2013 under REA grant
Dumbacher et al. Molecular Neurodegeneration  (2018) 13:50 Page 19 of 21
agreement n [289581] NPlast and by a fund of the “Agentschap Innoveren en
Ondernemen” of Flanders. JT holds an ERC Advanced Grant, CYRE N°340941.
Availability data and materials
All relevant data are available from the authors upon reasonable request.
Authors’ contributions
MD, TVD, KP, GG designed experiments and wrote the manuscript. MD, TVD,
KP performed most of the experiments. MF generated electrophysiology
data. AM, PC, SA and AK designed the chemistry. SS did the molecular
modelling. CCH supervised and contributed to the design of experiments.
GG directed the study. All authors read and approved the final manuscript.
Ethics approval and consent to participate
All experimental procedures were performed in accordance with the Guide
for the Care and Use of Laboratory Animals (NRC, 2011) and the European




MD, TVD, KP, KDW and GG are employed by reMYND. TVD, KP, KDW, GG, SW
and JW own reMYND warrants and/or stocks. MF employed by E-Phy-Science
and owns stocks. SL is employed by Orionis Biosciences. SW employed by ViroVet
and owns stocks.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Author details
1reMYND NV, Gaston Geenslaan 1, Leuven-Heverlee 3001, Belgium.
2E-Phy-Science, IPMC, 660 route des Lucioles, 06560 Sophia Antipolis, France.
3Orionis Biosciences, Technologiepark 12B, Zwijnaarde-Ghent 9052, Belgium.
4Cytokine Receptor Lab, Flanders Institute of Biotechnology, Medical
Biotechnology Center, Faculty of Medicine and Health Sciences, Ghent
University, Albert Baertsoenkaai 3, 9000 Ghent, Belgium. 5Department of
Chemistry, KU Leuven, Celestijnenlaan 200f - box 2404, Leuven-Heverlee
3001, Belgium. 6ViroVet NV, Ambachtenlaan 1, Leuven-Heverlee 3001,
Belgium. 7Department of Biology, Functional Biology, KU Leuven, Kasteelpark
Arenberg 31 box 2433, Leuven-Heverlee 3001, Belgium. 8Cistim Leuven vzw,
Gaston Geenslaan 2, Leuven-Heverlee 3001, Belgium. 9Center for Drug
Design and Development (CD3), KU Leuven, Waaistraat 6, 3000 Leuven,
Belgium. 10Cell Biology, Department of Biology, Faculty of Science, Utrecht
University, 3584CH Utrecht, The Netherlands.
Received: 4 December 2017 Accepted: 13 September 2018
References
1. LaFerla FM. Calcium dyshomeostasis and intracellular signalling in Alzheimer’s
disease. Nat Rev Neurosci. 2002;3:862–72.
2. Bookheimer SY, et al. Patterns of brain activation in people at risk for
Alzheimer’s disease. N Engl J Med. 2000;343:450–6.
3. Elman J a, et al. Neural compensation in older people with brain amyloid-β
deposition. Nat Neurosci. 2014;17:1316–8.
4. Sperling RA, et al. Amyloid deposition is associated with impaired default
network function in older persons without dementia. Neuron. 2009;63:178–88.
5. Busche MA, et al. Clusters of hyperactive neurons near amyloid plaques in a
mouse model of Alzheimer’s disease. Science. 2008;321:1686–9.
6. Bezprozvanny I, Mattson MP. Neuronal calcium mishandling and the
pathogenesis of Alzheimer’s disease. Trends Neurosci. 2008;31:454–63.
7. Morris M, Maeda S, Vossel K, Mucke L. The many faces of tau. Neuron.
2011;70:410–26.
8. Holth JK, et al. Tau loss attenuates neuronal network Hyperexcitability in
mouse and Drosophila genetic models of epilepsy. J Neurosci. 2013;33:1651–9.
9. Ittner LM, Götz J. Amyloid-β and tau--a toxic pas de deux in Alzheimer’s
disease. Nat Rev Neurosci. 2011;12:65–72.
10. Hall AM, et al. Tau-dependent Kv4.2 depletion and dendritic hyperexcitability
in a mouse model of Alzheimer’s disease. J Neurosci. 2015;35:6221–30.
11. Roberson ED, et al. Reducing endogenous tau ameliorates amyloid
beta-induced deficits in an Alzheimer’s disease mouse model. Science.
2007;316:750–4.
12. Zempel H, Thies E, Mandelkow E, Mandelkow E-M. Abeta oligomers cause
localized ca(2+) elevation, missorting of endogenous tau into dendrites, tau
phosphorylation, and destruction of microtubules and spines. J Neurosci.
2010;30:11938–50.
13. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration:
lessons from the Alzheimer’s amyloid beta-peptide. Nat. Rev. Mol. Cell
Biol. 2007;8:101–12.
14. Spires-Jones TL, Hyman BT. The intersection of amyloid beta and tau at
synapses in Alzheimer’s disease. Neuron. 2014;82:756–71.
15. Van Dooren, T., Princen, K., De Witte, K. & Griffioen, G. Derailed intraneuronal
signalling drives pathogenesis in sporadic and familial Alzheimer’s disease.
Biomed Res Int (2014) 2014, 167024.
16. Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis.
Science. 1992;256:184–5.
17. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: Progress
and problems on the road to therapeutics. Science. 2002;297:353–6.
18. Vossel KA, et al. Seizures and epileptiform activity in the early stages of
Alzheimer disease. JAMA Neurol. 2013;70:1158–66.
19. Sanchez PE, et al. Levetiracetam suppresses neuronal network dysfunction
and reverses synaptic and cognitive deficits in an Alzheimer’s disease
model. Proc Natl Acad Sci. 2012;109:E2895–903.
20. Vossel KA, Tartaglia MC, Nygaard HB, Zeman AZ, Miller BL. Epileptic
activity in Alzheimer’s disease: causes and clinical relevance. Lancet
Neurol. 2017;16:311–22.
21. Moechars D, et al. Early phenotypic changes in transgenic mice that
overexpress different mutants of amyloid precursor protein in brain. J Biol
Chem. 1999;274:6483–92.
22. Dewachter I, et al. Aging increased amyloid peptide and caused amyloid
plaques in brain of old APP/V717I transgenic mice by a different
mechanism than mutant presenilin1. J Neurosci. 2000;20:6452–8.
23. Everett KL, Cooper DMF. An improved targeted cAMP sensor to study the
regulation of adenylyl cyclase 8 by Ca2+ entry through voltage-gated
channels. PLoS One. 2013;8:1–11.
24. Schrödinger LLC. In: LLC S, editor. Small-molecule drug discovery suite
2016–2. New York; 2016.
25. Chandra A, et al. The GDI-like solubilizing factor PDEδ sustains the spatial
organization and signalling of Ras family proteins. Nat Cell Biol.
2012;14:148–58.
26. Risseeuw MDP, et al. A “clickable” MTX reagent as a practical tool for
profiling small-molecule-intracellular target interactions via MASPIT.
ChemMedChem. 2013;8:521–6.
27. Rezwan M, Auerbach D. Yeast “N”-hybrid systems for protein–protein and
drug–protein interaction discovery. Methods. 2012;57:423–9.
28. Jämsä A, Hasslund K, Cowburn RF, Bäckström A, Vasänge M. The retinoic
acid and brain-derived neurotrophic factor differentiated SH-SY5Y cell line
as a model for Alzheimer’s disease-like tau phosphorylation. Biochem
Biophys Res Commun. 2004;319:993–1000.
29. Anekonda TS, et al. L-type voltage-gated calcium channel blockade with
isradipine as a therapeutic strategy for Alzheimer’s disease. Neurobiol Dis.
2011;41:62–70.
30. Grewal SS, et al. Neuronal calcium activates a Rap1 and B-Raf signaling
pathway via the cyclic adenosine monophosphate-dependent protein
kinase. J Biol Chem. 2000;275:3722–8.
31. Pei J-J, et al. Up-regulation of mitogen-activated protein kinases ERK1/2 and
MEK1/2 is associated with the progression of neurofibrillary degeneration in
Alzheimer’s disease. Mol Brain Res. 2002;109:45–55.
32. Marambaud P, Dreses-Werringloer U, Vingtdeux V. Calcium signaling in
neurodegeneration. Mol Neurodegener. 2009;4:20.
33. Hanzal-Bayer M, Renault L, Roversi P, Wittinghofer A, Hillig RC. The complex of
Arl2-GTP and PDE delta: from structure to function. EMBO J. 2002;21:2095–106.
34. Hancock JF. Ras proteins: different signals from different locations. Nat Rev
Mol Cell Biol. 2003;4:373–85.
35. Nancy V, et al. The delta subunit of retinal rod cGMP phosphodiesterase
regulates the membrane association of Ras and rap GTPases. J Biol Chem.
2002;277:15076–84.
36. Glatter T, Wepf A, Aebersold R, Gstaiger M. An integrated workflow for
charting the human interaction proteome: insights into the PP2A system.
Mol Syst Biol. 2009;5(237).
Dumbacher et al. Molecular Neurodegeneration  (2018) 13:50 Page 20 of 21
37. Ismail S a, et al. Arl2-GTP and Arl3-GTP regulate a GDI-like transport system
for farnesylated cargo. Nat Chem Biol. 2011;7:942–9.
38. Wätzlich D, et al. The interplay between RPGR, PDEδ and Arl2/3 regulate the
ciliary targeting of farnesylated cargo. EMBO Rep. 2013;14:465–72.
39. Baehr W. Membrane protein transport in photoreceptors: the function of
PDEδ: the Proctor lecture. Invest Ophthalmol Vis Sci. 2014;55:8653–66.
40. Zimmermann G, et al. Small molecule inhibition of the KRAS–PDEδ
interaction impairs oncogenic KRAS signalling. Nature. 2013;497:638–42.
41. Schmick M, et al. KRas localizes to the plasma membrane by spatial cycles
of Solubilization, trapping and vesicular transport. Cell. 2014;157:459–71.
42. York RD, et al. Rap1 mediates sustained MAP kinase activation induced by
nerve growth factor. Nature. 1998;392:622–6.
43. Mochizuki N, et al. Spatio-temporal images of growth-factor-induced
activation of Ras and Rap1. Nature. 2001;411:1065–8.
44. Wu GY, Deisseroth K, Tsien RW. Spaced stimuli stabilize MAPK pathway
activation and its effects on dendritic morphology. Nat Neurosci. 2001;4:151–8.
45. Ohba Y. Mechanism of the spatio-temporal regulation of Ras and Rap1.
EMBO J. 2003;22:859–69.
46. Wang Z, et al. Rap1-Mediated Activation of Extracellular Signal-Regulated
Kinases by Cyclic AMP Is Dependent on the Mode of Rap1 Activation Rap1-
Mediated Activation of Extracellular Signal-Regulated Kinases by Cyclic AMP Is
Dependent on the Mode of Rap1 Activation. Mol Cell Biol. 2006;26:2130–45.
47. de Rooij J, et al. Epac is a Rap1 guanine-nucleotide-exchange factor directly
activated by cyclic AMP. Nature. 1998;396:474–7.
48. Kim J, Wei D, Hoffman DA. Kv4 potassium channel subunits control action
potential repolarization and frequency-dependent broadening in rat
hippocampal CA1 pyramidal neurones. J Physiol. 2005;569:41–57.
49. Morozov A, et al. Rap1 couples cAMP signaling to a distinct pool of p42/
44MAPK regulating excitability, synaptic plasticity, learning, and memory.
Neuron. 2003;39:309–25.
50. Purgert C a, et al. Intracellular mGluR5 can mediate synaptic plasticity in the
Hippocampus. J Neurosci. 2014;34:4589–98.
51. Gladding CM, Fitzjohn SM, Molnár E, Molnar E. Metabotropic glutamate
receptor-mediated long-term depression: molecular mechanisms.
Pharmacol Rev. 2009;61:395–412.
52. Gallagher SM. Extracellular signal-regulated protein kinase activation is
required for metabotropic glutamate receptor-dependent long-term
depression in hippocampal area CA1. J Neurosci. 2004;24:4859–64.
53. Jong Y-JI, Sergin I, Purgert C, O’Malley KL. Location-dependent signaling of
the group 1 metabotropic glutamate receptor mGlu5. Mol Pharmacol. 2014;
86:774–85.
54. Yuan L, Adams JP, Swank M, Sweatt JD, Johnston D. Protein kinase
modulation of dendritic K+ channels in hippocampus involves a mitogen-
activated protein kinase pathway. J Neurosci. 2002;22:4860–8.
55. Scala F, et al. Intraneuronal Aβ accumulation induces hippocampal neuron
hyperexcitability through A-type K+ current inhibition mediated by
activation of caspases and GSK-3. Neurobiol Aging. 2015;36:886–900.
56. Ping Y, et al. Linking Abeta42-induced Hyperexcitability to neurodegeneration,
learning and motor deficits, and a shorter lifespan in an Alzheimer’s model.
PLoS Genet. 2015;11:1–25.
57. Snyder EM, et al. Internalization of ionotropic glutamate receptors in
response to mGluR activation. Nat Neurosci. 2001;4:1079–85.
58. Subramanian J, Dye L, Morozov A. Rap1 signaling prevents L-type
calcium channel-dependent neurotransmitter release. J Neurosci.
2013;33:7245–52.
59. Catterall WA. Voltage-Gated Calcium Channels. Cold Spring Harb. Perspect.
Biol. 3; 2011. p. a003947.
60. Sawada M, Sato M. The effect of dimethyl sulfoxide on the neuronal
excitability and cholinergic transmission in Aplysia ganglion cells. Ann N Y
Acad Sci. 1975;243:337–57.
61. Morley P, Whitfield JF. The differentiation inducer, dimethyl sulfoxide,
transiently increases the intracellular calcium ion concentration in various
cell types. J Cell Physiol. 1993;156:219–25.
62. Terwel D, et al. Changed conformation of mutant tau-P301L underlies the
moribund Tauopathy, absent in progressive, nonlethal Axonopathy of tau-
4R/2N transgenic mice. J Biol Chem. 2005;280:3963–73.
63. Zhang B, et al. Retarded axonal transport of R406W mutant tau in transgenic
mice with a neurodegenerative tauopathy. J Neurosci. 2004;24:4657–67.
64. Zhang H, Constantine R, Frederick JM, Baehr W. The prenyl-binding protein PrBP/
δ: a chaperone participating in intracellular trafficking. Vis Res.
2012;75:19–25.
65. Bero AW, et al. Neuronal activity regulates the regional vulnerability to
amyloid-β deposition. Nat Neurosci. 2011;14:750–6.
66. Palop JJ, et al. Aberrant excitatory neuronal activity and compensatory
remodeling of inhibitory hippocampal circuits in mouse models of
Alzheimer’s disease. Neuron. 2007;55:697–711.
67. Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development.
Neurotherapeutics. 2007;4:18–61.
68. Bernard C, et al. Acquired dendritic channelopathy in temporal lobe epilepsy.
Science. 2004;305:532–5.
69. Lugo JN, et al. Altered phosphorylation and localization of the A-type
channel, Kv4.2 in status epilepticus. J Neurochem. 2008;106:1929–40.
70. Zhang Z, et al. GABAB receptor promotes its own surface expression by
recruiting a Rap1-dependent signaling cascade. J Cell Sci. 2015;128:2302–13.
71. Cagnol S, Chambard J-C. ERK and cell death: mechanisms of ERK-
induced cell death--apoptosis, autophagy and senescence. FEBS J.
2010;277:2–21.
72. Chong YH, et al. ERK1/2 activation mediates Abeta oligomer-induced
neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic
hippocampal slice cultures. J Biol Chem. 2006;281:20315–25.
73. Satoh T, et al. Neuroprotection by MAPK / ERK kinase inhibition with U0126
against oxidative stress in a mouse neuronal cell line and rat primary
cultured cortical neurons. Neurosci Lett. 2000;288:163–6.
74. Amadoro G, et al. NMDA receptor mediates tau-induced neurotoxicity by
calpain and ERK/MAPK activation. Proc Natl Acad Sci U S A. 2006;103:2892–7.
75. Feld M, et al. Decrease of ERK/MAPK overactivation in prefrontal cortex
reverses early memory deficit in a mouse model of Alzheimer’s disease. J
Alzheimers Dis. 2014;40:69–82.
76. Yau KW, et al. Microtubule minus-end binding protein CAMSAP2 controls
axon specification and dendrite development. Neuron. 2014;82:1058–73.
77. Klein WL. Abeta toxicity in Alzheimer’s disease: globular oligomers (ADDLs)
as new vaccine and drug targets. Neurochem Int. 2002;41:345–52.
Dumbacher et al. Molecular Neurodegeneration  (2018) 13:50 Page 21 of 21
